$MGX

Irish Jian sold $5K of MGX

Irish Jian (See Remarks) sold 3,737 shares of Metagenomi Therapeutics, Inc. (MGX) at $1.30 on 2026-06-05.

Original reporting
SEC EDGAR · Irish Jian
Published Jun 10, 2026, 3:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 3:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MGX
Neutral
medium confidence
Mentioned
$MGX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGXNeutralLow
01

Why it matters

The disclosed fact is an open-market sale by an officer/director; it may slightly affect sentiment but does not introduce new operational, clinical, or financial information.

02

Market read

Traders may note the insider sale for sentiment monitoring, but the transaction size is small and unlikely to drive price action alone.

03

What to watch

The article does not state whether the sale was for tax/expense needs or whether other insiders are buying; also, the absence of a stated 10b5-1 plan does not by itself imply bearish intent.

Relevance 3/10Novelty 2/10Timing: SEC Form 4 filed June 10 (transaction dated June 5)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Metagenomi Therapeutics, Inc.

Company-level read

Ticker impact

$MGXNeutralMedium confidence
Context

Metagenomi Therapeutics insider Irish Jian sold 3,737 shares at $1.2990/share in an open-market transaction disclosed via SEC Form 4.

Expected impact

Low near-term impact; any effect is likely limited to sentiment rather than a fundamental repricing.

Evidence & confidence

The filing is a small-value insider sale (~$4.9k) with no 10b5-1 plan stated; size is modest and does not indicate a new corporate event.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/taxes and do not necessarily reflect negative views on the company’s prospects.

Key entities

  • Metagenomi Therapeutics, Inc.

    MGX, the company whose insider transaction is disclosed.

  • Irish Jian

    Officer/Director who sold 3,737 shares at $1.2990/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGXMed

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).